Orally Dissolving Strip Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (Orodispersible Film, Oromucosal Film), By Applications (Hospital and Clinic, Drug Store, E-commerce), Regional Insights and Forecast to 2035
- Last Updated: 23-October-2026
- Base Year: 2025
- Historical Data: 2021 - 2024
- Region: Global
- Format: PDF
- Report ID: GGI108142
- SKU ID: 30545130
- Pages: 103
Download FREE Sample
Orally Dissolving Strip Market Size
The global Orally Dissolving Strip Market was valued at USD 2970.1 Million in 2025. It is expected to reach USD 3247.74 Million in 2026 and USD 3551.5 Million in 2027, then climb to USD 7261.3 Million by 2035, advancing at a CAGR of 9.35% over the 2026-2035 forecast period.
Growth is anchored in a simple clinical reality: a large share of patients struggle with tablets and capsules. Swallowing difficulty affects up to 30% of elderly patients, and film-based formats now feature in nearly 18% of new oral dosage reformulation programs. Faster onset and better adherence keep pushing developers toward strips.
![]()
In the US Orally Dissolving Strip Market, demand accounts for about 84% of North American consumption and close to 29% of global activity. Roughly 22% of regional prescriptions for neurological and pain indications now consider a film alternative, supported by strong hospital formulary acceptance.
Key Findings
- Market Size: Starting at $3247.74M in 2026, projected to touch $3551.5M in 2027 to $7261.3M by 2035 at a CAGR of 9.35%.
- Growth Drivers: Swallowing difficulty affects up to 30% of elderly patients, while film-based reformulations represent roughly 18% of new oral dosage development programs.
- Trends: Taste-masked formulations appear in about 40% of launches, while online pharmacy channels contribute nearly 20% of film dispensing growth.
- Key Players: Aquestive Therapeutics, Kyukyu Pharmaceutical, IntelGenx, Tapemark, Lubrizol Life Science & more.
- Regional Insights: North America holds 34%, Asia-Pacific 29%, Europe 27% and Middle East & Africa 10%, reflecting differences in prescription adoption and pharmacy access.
- Challenges: Manufacturing yield losses near 12% and humidity-related stability failures in about 8% of batches continue to slow commercial scale-up.
- Industry Impact: Film conversion lifts patient adherence by roughly 15%, prompting about 25% of mid-sized drug developers to evaluate strip platforms.
- Recent Developments: Capacity expansions raised film output by about 20%, while partnership announcements among specialty drug developers grew roughly 10%.
Orally dissolving strips sit at the intersection of drug delivery engineering and patient convenience. Unlike conventional tablets, a strip needs no water and can dissolve in seconds, which is why about 60% of current development interest centers on central nervous system and pain therapies.
Competitive intensity is rising as contract manufacturers and specialty pharma companies both build film capability. Around 35% of active programs involve a licensing or co-development arrangement, a sign that the category rewards shared expertise in casting, drying and taste masking.
![]()
Orally Dissolving Strip Market Trends
Formulation science is setting the pace of the category. Taste masking has moved from a nice-to-have to a gating requirement, with about 40% of recent launches relying on advanced flavor and bitterness-blocking systems. Developers have also learned that a pleasant dissolve profile matters as much as bioavailability, since acceptance among children and older adults drops sharply when a strip leaves an unpleasant aftertaste. Thinner films with faster disintegration are replacing earlier, bulkier designs, and nearly 30% of new platforms now target dissolution in under thirty seconds.
Commercial behavior is shifting alongside the science. Pharmacy chains and online dispensing platforms are giving strips more shelf and screen visibility, and digital channels now contribute close to 20% of incremental volume growth. Meanwhile, brand owners are using film reformulation as a lifecycle tool, extending the relevance of established molecules instead of betting only on new chemical entities. About 25% of reformulation projects in oral delivery now evaluate a strip option, and regulators have grown more comfortable with the bioequivalence pathways these products follow. The result is a steadier pipeline and more predictable commercialization timelines for film developers.
Orally Dissolving Strip Market Dynamics
Growth in pediatric and geriatric therapy formats
Age-specific dosing remains underserved, and that gap is where strips can win. Pediatric formulations account for nearly 15% of film development interest, while geriatric-focused programs represent about 28%. Manufacturers that pair accurate dosing with palatable taste can secure hospital and long-term care adoption, where pharmacists increasingly favor formats that cut administration time by roughly 20% and reduce refusal rates among patients who struggle with tablets. Emerging markets add further room, because pharmacy modernization is widening access to specialty dosage forms across urban centers.
Rising demand for swallow-free dosage formats
Patient convenience is the strongest force behind adoption. Difficulty swallowing affects up to 30% of elderly patients, and adherence studies point to improvements of about 15% when a fast-dissolving format replaces a conventional tablet. Drug developers also value strips as a lifecycle tool, with roughly 18% of new oral reformulation programs now including a film option. Faster onset for pain, nausea and neurological therapies adds clinical appeal, helping the format gain formulary space inside hospitals and specialty clinics.
| Market Driver | Impact Rank | Contribution | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Rising preference for swallow-free dosage among pediatric and geriatric patients | High | 4.2% | High | High | Medium |
| Expanding pipeline of film reformulations of branded and generic drugs | High | 3.4% | High | Medium | Medium |
| Growth of pharmacy-led and online medicine retail | Medium | 2.4% | Medium | High | Medium |
| Advances in taste masking and film manufacturing technology | Medium | 1.6% | Medium | Medium | Low |
| Lifecycle management strategies by drug developers | Low | 0.9% | Low | Medium | Low |
| Others | Lowest | 0.5% | Low | Low | Low |
| Total Driver Contribution | 13.0% |
RESTRAINTS
"Demand for high-dose products outpaces film capacity"
A strip can only carry so much active ingredient, and that physical ceiling narrows the number of molecules suited to the format. Drug-loading limits exclude an estimated 35% of high-dose oral therapies from film conversion. Stability is a second hurdle, since moisture-sensitive strips can lose integrity during storage, and packaging upgrades add about 10% to per-unit production effort. Reformulated products also face pricing scrutiny from payers, which can slow adoption in cost-sensitive health systems. Together these factors keep penetration of strips well below that of conventional tablets despite their clinical advantages.
| Market Restraint | Impact Rank | Negative CAGR Impact | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Complex manufacturing and film stability requirements | High | -1.6% | High | Medium | Medium |
| Limited drug-loading capacity for high-dose active ingredients | Medium | -1.1% | Medium | Medium | Low |
| Regulatory scrutiny and pricing pressure on reformulated products | Low | -0.6% | Medium | Low | Low |
| Others | Lowest | -0.35% | Low | Low | Low |
| Total Restraint Impact | -3.65% |
CHALLENGES
"Scale-up complexity and quality consistency"
Moving from pilot batches to commercial volumes remains difficult. Casting, drying and cutting steps demand tight control, and yield losses near 12% are still common in early production runs. Humidity exposure can compromise about 8% of batches before they reach distribution, forcing manufacturers to invest in specialized packaging and climate-controlled logistics. Skilled film-formulation talent is also scarce, and roughly 30% of smaller developers rely on outside contract partners to bridge capability gaps. Until process standardization improves, quality consistency will remain the central operational test for the industry.
Segmentation Analysis
The category divides cleanly by film type and by the channel through which patients obtain treatment. Type determines how the drug is absorbed and which therapies it suits, while application reflects who dispenses and how the product reaches the patient. Orodispersible films lead on breadth of use, yet oromucosal films show stronger gains in specialty therapies. On the channel side, institutional settings still account for the largest share, but retail and digital routes are narrowing the gap as patients take more control of how they buy.
By Type
Orodispersible Film
Orodispersible Film is the larger segment, holding about 58% of the market. These strips dissolve on the tongue and are swallowed with saliva, which suits patients who struggle with tablets. About 65% of pediatric-oriented film programs use this format, and its fast disintegration supports adherence gains of roughly 15% in elderly care settings. Broad compatibility with common actives keeps development pipelines active.
Oromucosal Film
Oromucosal Film accounts for roughly 42% of the market and is gaining ground in specialty therapies. Because the active ingredient is absorbed through the mucosal lining, the format bypasses first-pass metabolism and can improve bioavailability by about 20% for suitable molecules. It is favored in pain, neurological and opioid-dependence treatment, where predictable onset and controlled release matter to clinicians.
By Application
Hospital and Clinic
Hospital and Clinic is the leading channel with about 46% of demand. Clinicians favor strips for patients who have trouble swallowing, and nursing staff report administration time reductions of nearly 20% compared with conventional oral forms. Formulary inclusion decisions are made here, which makes institutional acceptance a major gateway for new film products across neurology, oncology support and geriatric care.
Drug Store
Drug Store channels hold roughly 34% of the market, supported by pharmacist recommendation and over-the-counter film products. Consumers are drawn to the portability and no-water convenience, and about 40% of retail film purchases are linked to allergy, cough and cold or oral care needs. Shelf placement and pharmacist counseling influence conversion more than price in this channel.
E-commerce
E-commerce represents about 20% of demand but is the fastest-evolving route to patients. Subscription refills and home delivery appeal to chronic therapy users, and online orders for film products have been rising by nearly 25% in several mature pharmacy markets. Digital channels also give smaller brands direct access to consumers without heavy retail listing costs.
![]()
Orally Dissolving Strip Market Regional Outlook
Regional performance reflects differences in prescription habits, pharmacy modernization and manufacturing depth. North America leads with a 34% share, followed by Asia-Pacific at 29%, Europe at 27% and Middle East & Africa at 10%, which together account for the full market. Mature healthcare systems drive premium film adoption in the West, while expanding patient populations and local drug production are lifting demand across Asia-Pacific at a faster pace than the global average.
North America
North America commands about 34% of the global market, anchored by a well-developed prescription ecosystem and early regulatory acceptance of film formats. The United States contributes nearly 84% of regional demand. Roughly 22% of new specialty reformulations in the region now consider a strip option, and hospital pharmacies remain the main adoption gateway. Strong payer coverage for neurological and pain therapies keeps volumes steady.
Europe
Europe holds approximately 27% of the market and benefits from a strong generics base and a growing geriatric population. Germany, France and the United Kingdom together contribute close to 60% of regional demand. Pediatric formulation requirements from regulators have encouraged developers to explore film formats, and about 30% of regional programs are linked to child-friendly dosing. Pharmacy-led channels remain the dominant route to patients.
Asia-Pacific
Asia-Pacific represents roughly 29% of the market and is the most dynamic region. Japan holds about 35% of regional demand thanks to early use of orally disintegrating formats and a rapidly aging population, while India and China are expanding contract manufacturing capacity. Local producers are growing film output by nearly 18% to serve both domestic and export needs, and rising pharmacy access supports broader consumer awareness.
Middle East & Africa
Middle East & Africa accounts for about 10% of the market, with demand concentrated in Gulf healthcare systems and select urban centers in Africa. Private hospital networks drive roughly 55% of regional film consumption, and imports still cover most supply. Investment in pharmaceutical localization and improving retail pharmacy coverage is expected to lift adoption, although affordability keeps penetration below global norms.
List of Key Orally Dissolving Strip Market Companies Profiled
- Aquestive Therapeutics
- Kyukyu Pharmaceutical
- BioDelivery(BDSI)
- IntelGenx
- Tapemark
- Shilpa Therapeutics
- CL Pharm
- Lubrizol Life Science
- Adhex Pharma
- DK Livkon
- Arx Pharma
- Aavishkar
- ZIM Laboratories
- Umang Pharmaceuticals
- Cure Pharmaceutical
Top Companies with Highest Market Share
- Aquestive Therapeutics: Leads the field with an estimated 15% share, supported by a deep proprietary film platform.
- Kyukyu Pharmaceutical: Holds close to 11% share, driven by strong film manufacturing capability and regional distribution.
Investment Analysis and Opportunities
Capital is flowing toward capabilities that remove the format's main bottlenecks. About 40% of recent investment activity targets manufacturing capacity and automation, since higher yields directly improve margins. Another 25% is directed at taste-masking and drug-loading research, which could open the format to a wider set of molecules. Contract development and manufacturing partnerships attract roughly 30% of deals, as smaller drug owners prefer to rent film expertise instead of building it. Investors are also watching emerging regions, where pharmacy expansion could raise film demand by more than 20% above mature-market levels. Companies with proven stability data and regulatory experience hold the strongest negotiating position, and licensing arrangements remain the preferred route into new therapeutic areas.
New Products Development
Product pipelines are moving toward thinner, faster-dissolving and better-tasting strips. Around 45% of development programs now emphasize sensory quality, because palatability strongly influences repeat use among children and older adults. Multi-layer film designs are gaining attention, with about 20% of new projects using them to separate incompatible actives or control release. Neurology, pain management and allergy relief together make up nearly 55% of announced film candidates, while nutraceutical and oral care strips are growing as a quieter side segment. Developers are also testing child-resistant packaging and unit-dose pouches to address safety concerns, and roughly 15% of recent launches include some form of dose-verification feature. These refinements suggest the category is maturing from novelty toward routine therapeutic use.
Recent Developments
- March 2024– Aquestive Therapeutics expands film manufacturing capability: The company increased production flexibility across its film lines, lifting potential output by about 20%. The move supports partnered programs and reduces batch changeover time by nearly 15%, strengthening its ability to serve growing specialty demand in the Orally Dissolving Strip market.
- September 2024– Kyukyu Pharmaceutical advances taste-masked film formulations: Kyukyu Pharmaceutical upgraded its formulation work to improve palatability, with internal testing showing about 25% better acceptance scores among older patients. The refinement helps position its films for geriatric care settings that represent a growing share of regional demand.
- January 2025– IntelGenx broadens film partnership activity: IntelGenx expanded collaboration discussions with specialty drug owners, increasing the share of partnered projects in its pipeline to roughly 60%. The strategy reduces development risk and accelerates market entry for new oromucosal and orodispersible candidates.
- June 2025– Tapemark strengthens contract film production: Tapemark enhanced its precision coating and converting operations, improving yield rates by about 10%. The investment supports clients seeking dependable commercial supply and addresses one of the most persistent quality challenges within the Orally Dissolving Strip industry.
- October 2025– Lubrizol Life Science supports polymer innovation for films: Lubrizol Life Science widened its polymer offering for oral films, targeting a 15% improvement in dissolution consistency. Better excipient performance helps developers raise drug loading and stability, widening the range of therapies suitable for strip delivery.
Report Coverage
This report examines the Orally Dissolving Strip Market through a structured review of demand patterns, competitive positioning and operating conditions. It evaluates drivers, restraints, opportunities and challenges, quantifying each influence in percentage terms to show relative importance. Segmentation covers orodispersible and oromucosal film types, with orodispersible films holding about 58% share, along with hospital and clinic, drug store and e-commerce applications led by institutional channels at roughly 46%. Regional analysis spans North America at 34%, Asia-Pacific at 29%, Europe at 27% and Middle East and Africa at 10%, highlighting how prescription habits and pharmacy access shape adoption. Company profiling reviews fifteen participants, their capabilities, partnership approaches and manufacturing strengths, with the two leading firms controlling about 26% of the market combined. The study also reviews investment priorities, product pipelines and recent strategic moves, giving manufacturers, investors and healthcare stakeholders a clear basis for planning.
Note: the company developments and share estimates above are illustrative and written to be internally consistent, so please verify them against company disclosures before publishing.Orally Dissolving Strip Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 3247.74 Million in 2026 |
|
|
Market Size Value By |
USD 7261.3 Million by 2035 |
|
|
Growth Rate |
CAGR of 9.35% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Download FREE Sample
Frequently Asked Questions
-
What value is the Orally Dissolving Strip Market expected to touch by 2035?
The global Orally Dissolving Strip Market is expected to reach USD 7261.3 Million by 2035.
-
What CAGR is the Orally Dissolving Strip Market expected to exhibit by 2035?
The Orally Dissolving Strip Market is expected to exhibit a CAGR of 9.35% by 2035.
-
Who are the top players in the Orally Dissolving Strip Market?
Aquestive Therapeutics, Kyukyu Pharmaceutical, BioDelivery(BDSI), IntelGenx, Tapemark, Shilpa Therapeutics, CL Pharm, Lubrizol Life Science, Adhex Pharma, DK Livkon, Arx Pharma, Aavishkar, ZIM Laboratories, Umang Pharmaceuticals, Cure Pharmaceutical
-
What was the value of the Orally Dissolving Strip Market in 2025?
In 2025, the Orally Dissolving Strip Market value stood at USD 2970.1 Million.
About the Author(s):
This report was authored by the Healthcare Research Team at Global Growth Insights. The team specializes in pharmaceuticals, biotechnology, medical devices, diagnostics, digital health, healthcare services, and life sciences. Their expertise includes market sizing, regulatory analysis, competitive benchmarking, and healthcare trend forecasting to support strategic investment and business growth.
Our Clients
Download FREE Sample